Nasdaq(NDAQ)
Search documents
History Says the Nasdaq Could Surge in 2025: 2 Stock-Split AI Stocks to Buy Now, According to Wall Street
The Motley Fool· 2025-01-09 08:59
The Nasdaq Composite (^IXIC -0.06%) advanced 29% in 2024, and history says that momentum could spill into 2025. Since its inception in 1971, the Nasdaq has gained over 20% in 20 years. Following those incidents, the technology-focused index returned an average of 16% in the next year.In other words, history says the Nasdaq could advance 16% in 2025, but most Wall Street analysts see even more upside in Nvidia (NVDA -0.02%) and Lam Research (LRCX -0.62%), two companies that reset their soaring share prices b ...
Nasdaq Reports December 2024 Volumes and 4Q24 Statistics
Globenewswire· 2025-01-08 21:05
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for December 2024, as well as quarterly volumes, estimated revenue capture, number of listings, and index statistics for the quarter ended December 31, 2024 on its Investor Relations website. A data sheet showing this information can be found at: http://ir.nasdaq.com/financials/volume-statistics. About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment mana ...
S&P 500 and Nasdaq to pull back further as dollar and bond yields rise
Proactiveinvestors NA· 2025-01-08 13:05
About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Prnewswire· 2025-01-08 13:00
CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per sha ...
History Says the Nasdaq Could Jump Higher in 2025: 2 Artificial Intelligence (AI) Stocks That Can Bounce Back and Soar 25% to 40%, According to Wall Street
The Motley Fool· 2025-01-08 09:40
Technology stocks were in fine form on the stock market in 2024, with the tech-laden Nasdaq Composite (^IXIC -1.89%) index clocking impressive gains of 28.6% last year following an even stronger jump of 43% in 2023.Historical trends indicate that the Nasdaq Composite could be on track to deliver more gains in 2025. In any year where the Nasdaq managed a 30%-plus gain overall, it averaged a 19% jump in the year that followed. Moreover, the Nasdaq averages a 17% return following a year in which it delivered r ...
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire News Room· 2025-01-07 13:00
MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 113,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires. The Op ...
Nasdaq set for flat start as Nvidia overtakes Apple as largest company
Proactiveinvestors NA· 2025-01-07 12:56
About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...
Here Are My Top 5 Nasdaq Stock to Buy in 2025
The Motley Fool· 2025-01-07 12:15
The Nasdaq Composite (^IXIC 1.24%) has been a great performing index, as it beat the broader S&P 500 (^GSPC 0.55%) in 2024 by rising 28.6% versus the S&P 500's 23.3%. It wouldn't surprise me to see those results again in 2025, but I think a few companies within the Nasdaq Composite can outperform the broader index in 2025.These stocks are Meta Platforms (META 4.23%), Alphabet (GOOG 2.50%) (GOOGL 2.65%), ASML (ASML 7.58%), PayPal (PYPL 2.20%), and MercadoLibre (MELI -1.90%). I think all five of these stocks ...
Nasdaq Jumps Over 1% As Nvidia, Micron Surge: Investor Fear Eases, But Greed Index Remains In 'Fear' Zone
Benzinga· 2025-01-07 11:19
The CNN Money Fear and Greed index showed some easing in the overall fear level, while the index remained in the “Fear” zone on Monday.U.S. stocks settled mostly higher on Monday, with the S&P 500 and Nasdaq Composite recording back-to-back gains during the session.Chip stocks were among the top gainers of the session after Foxconn disclosed record revenue for the fourth quarter. Nvidia Corp. NVDA shares gained 3.4%, while Micron Technology Inc. MU jumped 10.5% on Monday.Among Monday's notable headlines, Th ...
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Prnewswire· 2025-01-06 22:35
STATEN ISLAND, N.Y., Jan. 6, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,463,058 shares of its common stock at a purchase price of $1.015 per share in a registered direct offering priced at-the-market under Nasdaq rules. In ...